← Back to Clinical Trials
Recruiting Phase 1 NCT07346495

A Study of Remternetug (LY3372993) in Healthy Chinese Participants

Trial Parameters

Condition Healthy
Sponsor Eli Lilly and Company
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 24
Sex ALL
Min Age 18 Years
Max Age 45 Years
Start Date 2026-01-31
Completion 2026-08
Interventions
LY3372993Placebo

Brief Summary

The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 25 weeks, including screening period.

Eligibility Criteria

Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, electrocardiogram (ECG), and Magnetic resonance imaging (MRI). * Participants must be native Chinese. To qualify as Chinese for this study, the participant, the participant's biological parents, and all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China. * Have clinical laboratory test results within normal reference ranges for the population or study site, or results with acceptable deviations that are judged to be not clinically significant by the investigator. * Have a body mass index within the range 18.0 to 28.0 kilograms per square meter (kg/m²), inclusive. * Are individuals Assigned Male at Birth (AMAB) or individuals Assigned Female at Birth (AFAB) who are individuals not of childbearing potential (INOCBP). Individual of childbearing potential (IOCBP) are excluded from

Related Trials